Summary
AbbVie Inc. (ABBV) filed an 8-K on May 10, 2021, reporting the outcomes of its Annual Meeting of Stockholders held on May 7, 2021. The meeting saw the election of Class III Directors, the ratification of Ernst & Young LLP as the independent auditor, and approval of executive compensation on an advisory basis. Additionally, stockholders approved amendments to the 2013 Incentive Stock Program and the 2013 Employee Stock Purchase Plan for Non-U.S. Employees. Notably, two stockholder proposals did not pass: one seeking a lobbying report and another to require an independent board chair. A management proposal to eliminate supermajority voting provisions in the company's charter also failed to gain sufficient support. Overall, the meeting reflects strong stockholder support for board-approved matters and auditor independence, while also signaling a divergence on certain corporate governance initiatives proposed by stockholders and management.
Key Highlights
- 1Class III Directors Roxanne S. Austin, Richard A. Gonzalez, Rebecca B. Roberts, and Glenn F. Tilton were elected with significant "For" votes.
- 2Ernst & Young LLP was overwhelmingly ratified as AbbVie's independent registered public accounting firm for 2021.
- 3Stockholders approved, on an advisory basis, the compensation of named executive officers.
- 4Amendments to the 2013 Incentive Stock Program and the 2013 Employee Stock Purchase Plan for Non-U.S. Employees were approved.
- 5A management proposal to amend the certificate of incorporation to eliminate supermajority voting did not receive sufficient approval.
- 6A stockholder proposal to issue a lobbying report was not approved.
- 7A stockholder proposal to adopt a policy requiring an independent board chair was not approved.